The Cosmc connection to the Tn antigen in cancer
Open accessThe DOI matches its Crossref record; 206 of the 206 references it cites were found in a registry or an index.
Abstract
The Tn antigen is a tumor-associated carbohydrate antigen that is not normally expressed in peripheral tissues or blood cells. Expression of this antigen, which is found in a majority of human carcinomas of all types, arises from a blockage in the normal O-glycosylation pathway in which glycans are extended from the common precursor GalNAcα1-O-Ser/Thr (Tn antigen). This precursor is generated in the Golgi apparatus on newly synthesized glycoproteins by a family of polypeptide α-N-acetylgalactosaminyltransferases (ppGalNAcTs) and then extended to the common core 1 O-glycan Galβ1-3GalNAcα1-O-Ser/Thr (T antigen) by a single enzyme termed the T-synthase (core 1 β3-galactosyltransferase or C1GalT). Formation of the active form of the T-synthase requires a unique molecular chaperone termed Cosmc, encoded by Cosmc on the X-chromosome (Xq24 in humans, Xc3 in mice). Cosmc resides in the endoplasmic reticulum (ER) and prevents misfolding, aggregation, and proteasome-dependent degradation of newly synthesized T-synthase. Loss of expression of active T-synthase or Cosmc can lead to expression of the Tn antigen, along with its sialylated version Sialyl Tn antigen as observed in several cancers. Both genetic and epigenetic pathways, in addition to potential metabolic regulation, can result in abnormal expression of the Tn antigen. Engineered expression of the Tn antigen by disruption of either C1GalT (T-syn) or Cosmc in mice is associated with a tremendous range of pathologies and engineered expression of the Tn antigen in mouse embryos leads to embryonic death. Studies indicate that many membrane glycoproteins expressing the Tn antigen and/or truncated O-glycans may be dysfunctional, due to degradation and/or misfolding. Thus, expression of normal O-glycans is associated with health and homeostasis whereas truncation of O-glycans, e.g. the Tn and/or Sialyl Tn antigens is associated with cancer and other pathologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“have been noted as hallmarks of cancer [6], it is of-”
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679 · cited 1×
“in the United States and worldwide [1,2], despite de-”
Glycosylation in Cellular Mechanisms of Health and Disease
Ohtsubo, K., & Marth, J. D. (2006) · Cell · doi:10.1016/j.cell.2006.08.019 · Cited by 2,788
Intra-tumour heterogeneity: a looking glass for cancer?
Marusyk, A., Almendro, V., & Polyak, K. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3261 · Cited by 2,000
Mucins in cancer: protection and control of the cell surface
Hollingsworth, M. A., & Swanson, B. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1251 · Cited by 1,807 · cited 1×
“pression of some mucins is associated with the tumor phenotype [16,121,122].”
Van der Sluis, M., De Koning, B. A. E., De Bruijn, A. C. J. M., Velcich, A., Meijerink, J. P. P., Van Goudoever, J. B., Büller, H. A., Dekker, J., Van Seuningen, I., Renes, I. B., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.04.020 · Cited by 1,684 · cited 1×
“Among the GI tract mucins, MUC2, which is mainly synthesized and secreted by the goblet cells, is an important mucus layer component to protect epithelial cells [123].”
The urokinase-type plasminogen activator system in cancer metastasis: A review
Andreasen, P. A., Kjøller, L., Christensen, L., & Duffy, M. J. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970703)72:1<119::aid-ijc17>3.0.co;2-e · Cited by 1,552 · cited 1×
“One of the most useful mouse anti-Tn mAb is an IgM (CA3638, clone 12A8-C7-F5), one of several clones originally developed by Springer and colleagues, and useful in IHC and flow cytometry to detect the Tn antigen [171].”
T and Tn, General Carcinoma Autoantigens
Springer, G. F. (1984) · Science · doi:10.1126/science.6729450 · Cited by 1,009 · cited 1×
“Springer’s group developed specific monoclonal antibodies (mAbs) to the Tn antigen [98] and found that the Tn antigen was commonly expressed in many tumor cells [22].”
Colorectal Cancer in Mice Genetically Deficient in the Mucin Muc2
Velcich, A., Yang, W., Heyer, J., Fragale, A., Nicholas, C., Viani, S., Kucherlapati, R., Lipkin, M., Yang, K., & Augenlicht, L. (2002) · Science · doi:10.1126/science.1069094 · Cited by 936 · cited 1×
“MUC2 -deficient ( MUC2 − / − ) mice develop small and large intestinal and rectal tumors, indicating that loss of MUC2 could be an initiating event in intestinal tumorigenesis [124].”
Bennett, E. P., Mandel, U., Clausen, H., Gerken, T. A., Fritz, T. A., & Tabak, L. A. (2012) · Glycobiology · doi:10.1093/glycob/cwr182 · Cited by 876 · cited 2×
“A large set of approximately 20 different ppGalNAcTs, most of which have a catalytic domain and a separate lectin domain that binds the product of the reaction, leads to efficient modi-fication of specific Ser/Thr residues [43,47].”
Research works printed but not linked: 2
- [84]Ju T Otto VI Cummings RD The Tn antigen-structural simplicity and biological complexity Angew Chem Int Ed Engl 2011 50 8 1770 91 21259410 PMC7159538
- [87]Friedenreich V The Thomsen Hemagglutination Phenomenon: Production of a Specific Receptor Quality in Red Corpuscles by Bacterial Activity Dissertation Thesis Copenhagen Levin and Munksgaard 1930
Cited by
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
“Disruption of this layer by genetically altering mucin backbones, O-linked glycosyltransferases (or key chaperones like Cosmc) can have very serious consequences, including inflammation and carcinogenesis associated with microbial invasion (453) (454) (455) (456) .”
BackgroundProtein Glycosylation in Cancer
Stowell, S. R., Ju, T., & Cummings, R. D. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040438 · Cited by 873
“Once folded properly, the T-synthase moves to the Golgi apparatus, where it acts quantitatively on the products of the ppGalNAcTs to generate normal O-glycans (102).”
BackgroundInfluentialSelf-citationHallmarks of glycosylation in cancer
Munkley, J., & Elliott, D. J. (2016) · Oncotarget · doi:10.18632/oncotarget.8155 · Cited by 521
“Cancer cells characteristically express proteins with truncated O-glycan structures that are thought to be due to mutations or epigenetic silencing of the COSMC gene [95, 96], or to increased expression of ST6GalNAc1 [88].”
BackgroundSialic acids in cancer biology and immunity
Pearce, O. M. T., & Läubli, H. (2016) · Glycobiology · doi:10.1093/glycob/cwv097 · Cited by 470
Intestinal epithelial glycosylation in homeostasis and gut microbiota interactions in IBD
Kudelka, M. R., Stowell, S. R., Cummings, R. D., & Neish, A. S. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0331-7 · Cited by 355
Self-citationSimple Sugars to Complex Disease—Mucin-Type O-Glycans in Cancer
(2015) · Advances in Cancer Research · doi:10.1016/bs.acr.2014.11.002 · Cited by 260
“gen, alterations—either genetic or cell biologic—of the enzymes that synthesize the Tn antigen, changes in expression of nucleotide sugars or transporters, and changes in vesicular transport, retention, and structure of the Golgi/ER as well as alterations in glycosyltransferase oligomerization ( Ju et al., 2014).”
BackgroundInfluentialSelf-citationC-type lectin receptors in the control of T helper cell differentiation
Geijtenbeek, T. B. H., & Gringhuis, S. I. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.55 · Cited by 257
Tumor‐associated antigens: Tn antigen, sTn antigen, and T antigen
Fu, C., Zhao, H., Wang, Y., Cai, H., Xiao, Y., Zeng, Y., & Chen, H. (2016) · HLA · doi:10.1111/tan.12900 · Cited by 219
“Numerous studies have reported that the expression of Tn and sTn antigens in human tumor cells is related to dysfunctional Cosmc (8, 33).”
BackgroundSelf-citationEmerging structural insights into glycosyltransferase-mediated synthesis of glycans
Moremen, K. W., & Haltiwanger, R. S. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0350-2 · Cited by 209
“Stuck on sugars – how carbohydrates regulate cell adhesion, recognition, and signaling”
Cummings, R. D. (2019) · Glycoconjugate Journal · doi:10.1007/s10719-019-09876-0 · Cited by 161
Self-citationShort O-GalNAc glycans: regulation and role in tumor development and clinical perspectives
Chia, J., Goh, G. Y. L., & Bard, F. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.03.008 · Cited by 161
Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design
Beckwith, D. M., & Čudić, M. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101389 · Cited by 123
Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy
Mantuano, N. R., Natoli, M., Zippelius, A., & Laubli, H. P. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001222 · Cited by 127
Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets
Chugh, S., Gnanapragassam, V. S., Jain, M., Rachagani, S., Ponnusamy, M. P., & Batra, S. K. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.003 · Cited by 121
“inactivation of C1GALT1, which is associated with Tn syndrome [32].”
BackgroundCellular O-Glycome Reporter/Amplification to explore O-glycans of living cells
Kudelka, M. R., Antonopoulos, A., Wang, Y., Duong, D. M., Song, X., Seyfried, N. T., Dell, A., Haslam, S. M., Cummings, R. D., & Ju, T. (2015) · Nature Methods · doi:10.1038/nmeth.3675 · Cited by 104
Self-citationDusoswa, S. A., Verhoeff, J., Abels, E. R., Méndez‐Huergo, S. P., Croci, D. O., Kuijper, L. H., de Miguel, E., Wouters, V. M., Best, M. G., Rodríguez, E., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1907921117 · Cited by 101
“FG-Cosmc-KO or Gl261.”
MethodInfluentialSialic acid and biology of life: An introduction
Ghosh, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816126-5.00001-9 · Cited by 119
“sTn antigen generated by sialylation of Tn antigen [364] by ST6GalNAc I occurs rarely in healthy tissues but has been observed in epithelial cancer cells and breast tumors [365].”
Plant lectins and their usage in preparing targeted nanovaccines for cancer immunotherapy
Gupta, B., Sadaria, D., Warrier, V. U., Kirtonia, A., Kant, R., Awasthi, A., Baligar, P., Pal, J. K., Yuba, E., Sethi, G., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.005 · Cited by 89
Adaptation of the Golgi Apparatus in Cancer Cell Invasion and Metastasis
Bui, S., Mejia, I., Díaz, B., & Wang, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.806482 · Cited by 83
Self-citationO-glycan recognition and function in mice and human cancers
Cervoni, G. E., Cheng, J. J., Stackhouse, K. A., Heimburg‐Molinaro, J., & Cummings, R. D. (2020) · Biochemical Journal · doi:10.1042/bcj20180103 · Cited by 89
Self-citationUpregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth
Scott, E., Hodgson, K., de la Calle, B., Turner, H., Cheung, K., Bermudez, A., Garcia-Marques, F. J., Pye, H., Yo, E. C., Islam, M. K., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02604-x · Cited by 80
“Lectin arrays and flow cytometry revealed that GALNT7 overexpression correlates with increased binding of SBA lectin (which recognises the cancer-associated Tn antigen (35, 36)) (Figure 4A and Supplementary Figure 6).”
Galectin-Binding O-Glycosylations as Regulators of Malignancy
Dimitroff, C. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0834 · Cited by 80
Electronic single-molecule identification of carbohydrate isomers by recognition tunnelling
Im, J., Biswas, S., Liu, H., Zhao, Y., Sen, S., Biswas, S., Ashcroft, B. A., Borges, C. R., Wang, X., Lindsay, S. M., et al. (2016) · Nature Communications · doi:10.1038/ncomms13868 · Cited by 72
Pillay, P., Vatish, M., Duarte, R. A. B., Moodley, J., & Mackraj, I. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s208865 · Cited by 79
“It is possible that exosomal mediated dysregulation of Tn antigen synthesis may be an important recognition element, mediating cell-cell interactions involved in placental organotrophic metastasis.(27,64) Additionally, the upregulation of exosomal hsa-miR-122-5p in EOPE vs LOPE (LogFC 5.”
BackgroundAlterations of Golgi Structural Proteins and Glycosylation Defects in Cancer
Zhang, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.665289 · Cited by 72
“Besides, altered expression of the active T-synthase or Cosmc, an ER-localized molecular chaperone required for the stability and activity of T-synthase, can lead to the overexpression of the Tn antigen (Ju et al., 2014).”
BackgroundMadunić, K., Zhang, T., Mayboroda, O. A., Holst, S., Stavenhagen, K., Jin, C., Karlsson, N. G., Lageveen‐Kammeijer, G. S. M., & Wuhrer, M. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03504-z · Cited by 70
Liu, Z., Liu, J., Dong, X., Hu, X. Y., Jiang, Y., Li, L., Du, T., Yang, L., Wen, T., An, G., et al. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14117 · Cited by 71
“12‐14 Dysfunction in T‐synthase or Cosmc leads to the expression of Tn antigen, which is indeed a characteristic of abnormal O‐ glycosylation.(15,16) It has been reported that Tn antigen is detected in almost 90% of human colon cancer whereas it is rarely detected in normal tissue.”
BackgroundAberrant O‐glycosylation contributes to tumorigenesis in human colorectal cancer
Jiang, Y., Liu, Z., Xu, F., Dong, X., Cheng, Y., Hu, Y., Gao, T., Liu, J., Yang, L., Jia, X., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13752 · Cited by 75
“It is known that mature O‐glycosylation depends specifically on T‐synthase activity and its single chaperone‐Cosmc.(31) Besides, in colonic tissues, defective core 3 O‐glycosylation could also lead to the exposure of Tn antigen.”
BackgroundEffective utilization of quartz crystal microbalance as a tool for biosensing applications
Jandas, P. J., Prabakaran, K., Luo, J., & Holaday, M. G. D. (2021) · Sensors and Actuators A Physical · doi:10.1016/j.sna.2021.113020 · Cited by 59
A Sweet Warning: Mucin-Type O-Glycans in Cancer
Zhang, Y., Sun, L., Lei, C., Lei, C., Han, J., Zhang, J., & Zhang, J. (2022) · Cells · doi:10.3390/cells11223666 · Cited by 67
Gupta, R., Leon, F., Thompson, C. M., Nimmakayala, R. K., Karmakar, S., Nallasamy, P., Chugh, S., Prajapati, D. R., Rachagani, S., Sushil Kumar, K., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0772-3 · Cited by 66
da Costa, V., van Vliet, S. J., Carasi, P., Frigerio, S., García, P. A., Croci, D. O., Festari, M. F., Costa, M., Landeira, M., Rodríguez-Zraquia, S. A., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.012 · Cited by 63
Human B Cell Differentiation Is Characterized by Progressive Remodeling of O-Linked Glycans
Giovannone, N., Antonopoulos, A., Liang, J., Geddes-Sweeney, J., Kudelka, M. R., King, S. L., Lee, G. S., Cummings, R. D., Dell, A., Barthel, S. R., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02857 · Cited by 54
“Indeed, T-antigen expression and associated PNA binding is a feature of malignant transformation (7, 8).”
BackgroundSelf-citationProteomics, Glycomics, and Glycoproteomics of Matrisome Molecules
Raghunathan, R., Sethi, M. K., Klein, J., & Zaia, J. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r119.001543 · Cited by 57
“ize pathophysiologies of cancer (41, 42), autoimmune (43–45), cardiovascular (46–48), and neuropsychiatric diseases (23, 24, 34).”
BackgroundGlycans as Targets for Drug Delivery in Cancer
Diniz, F., Coelho, P., Duarte, H. O., Sarmento, B. F. C. C., Reis, C. A., & Gomes, J. (2022) · Cancers · doi:10.3390/cancers14040911 · Cited by 55
“Core 1 β3-Gal-T specific molecular chaperone (COSMC), localized in the ER, is necessary for the activation of C1GalT1 in the Golgi apparatus by preventing its misfolding, aggregation and proteasomal degradation [22].”
BackgroundZhou, D., Xu, L., Huang, W., & Tonn, T. (2018) · Molecules · doi:10.3390/molecules23061326 · Cited by 52
Mucin Glycans: A Target for Cancer Therapy
Sun, L., Zhang, Y., Li, W., Zhang, J., & Zhang, Y. (2023) · Molecules · doi:10.3390/molecules28207033 · Cited by 53
“COSMC is an ER-localized chaperone that interacts with newly synthesized C1GALT1 to promote the correct folding of C1GALT1 and keep C1GALT1 active [48].”
BackgroundAberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors
Matsumoto, Y., & Ju, T. (2023) · Cancers · doi:10.3390/cancers15143536 · Cited by 53
Self-citationStructure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides
Sharma, P. A., Marada, V. V. V. R., Cai, Q., Kizerwetter, M., He, Y., Wolf, S. P., Schreiber, K., Clausen, H., Schreiber, H. W., & Kranz, D. M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920662117 · Cited by 48
Translation of genome to glycome: role of the Golgi apparatus
Pothukuchi, P., Agliarulo, I., Russo, D., Rizzo, R., Russo, F., & Parashuraman, S. (2019) · FEBS Letters · doi:10.1002/1873-3468.13541 · Cited by 40
ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody
Sharma, S. K., Mack, K. N., Piersigilli, A., Pourat, J., Edwards, K. J., Keinänen, O. M., Jiao, M. S., Zhao, H., White, B., Brooks, C. L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1798 · Cited by 45
“…serve to form as a barrier that protects epithelial cells from mechanical forces and infection, altered glyco-forms of mucins expressed by transformed cells have been implicated in the induction of oncogenic features and the orchestration of the metastatic potential of cancer cells (6, 7).”
Matsumoto, Y., Kudelka, M. R., Hanes, M. S., Lehoux, S. D., Dutta, S. M., Jones, M. B., Stackhouse, K. A., Cervoni, G. E., Heimburg‐Molinaro, J., Smith, D. F., et al. (2019) · Glycobiology · doi:10.1093/glycob/cwz095 · Cited by 47
“The expression of the Tn antigen and sialylTn (STn) in tumors represent potential markers associated with poor prognosis and tumor metastasis (Ju et al. 2013; Ju et al. 2014; Kudelka et al. 2015; Stowell et al. 2015; Chia et al. 2016).”
BackgroundSelf-citationC1GALT1 in health and disease (Review)
Sun, X., Zhan, M., Sun, X., Liu, W., & Meng, X. (2021) · Oncology Letters · doi:10.3892/ol.2021.12850 · Cited by 47
“One study has demonstrated that numerous membrane glycoproteins expressing Tn antigen and/or truncated O‐glycans may be dysfunctional due to degra‐ dation and/or folding errors (82).”
BackgroundMucins as anti-cancer targets: perspectives of the glycobiologist
Brockhausen, I., & Melamed, J. (2021) · Glycoconjugate Journal · doi:10.1007/s10719-021-09986-8 · Cited by 44
Dong, X., Jiang, Y., Liu, J., Liu, Z., Gao, T., An, G., & Wen, T. (2018) · BioMed Research International · doi:10.1155/2018/9532389 · Cited by 37
Large-Scale and Site-Specific Mapping of the Murine Brain O-Glycoproteome with IMPa
Suttapitugsakul, S., Matsumoto, Y., Aryal, R. P., & Cummings, R. D. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c00408 · Cited by 34
Self-citationKurze, A.-K., Buhs, S., Eggert, D., Oliveira-Ferrer, L., Müller, V., Niendorf, A., Wagener, C., & Nollau, P. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0420-9 · Cited by 30
The role of glycosylation in clinical allergy and immunology
Hale, R. C., Morais, D., Chou, J. S., & Stowell, S. R. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.09.003 · Cited by 31
Role of tumor cell sialylation in pancreatic cancer progression
Marciel, M. P., Haldar, B., Hwang, J., Bhalerao, N., & Bellis, S. L. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2022.07.003 · Cited by 34
Role of Truncated O-GalNAc Glycans in Cancer Progression and Metastasis in Endocrine Cancers
Pinto, D., & Parameswaran, R. (2023) · Cancers · doi:10.3390/cancers15133266 · Cited by 35
“In cancer cells that lack COSMC and T-synthase, aberrant glycans are synthesised on the cell surface, which alters the intercellular dynamics, including that of cell recognition by glycan-binding proteins (GBPs) [15].”
InfluentialBhat, G. G., Hothpet, V., Lin, M., & Cheng, P. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.08.006 · Cited by 28
Zhang, C., Deng, X., Qiu, L., Peng, F., Geng, S., Shen, L., & Luo, Z. (2018) · Journal of Cancer · doi:10.7150/jca.25252 · Cited by 28
“It is well known that the mutation or loss of expression of Cosmc mediated aberrant O-glycosylation and promoted oncogenic properties in several cancers [42-44].”
BackgroundLi, C., Shi, J., & Zhao, Y. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26628 · Cited by 28
“Cosmcwas a specificmolecularmodulator in endoplasmic reticulum for the T-synthase, one Golgi ß1, 3-galactosyltransferase which synthesizes the Galß1, 3GalNAcα-Ser/Thr, in the glycoproteins.(37,38) The Cosmc dysfunction may lead to the inactive T-synthase formation and Tn antigen consequent expression, which was correl…”
BackgroundThe GalNAc-T Activation (GALA) Pathway: Drivers and markers
Chia, J., Tay, F. P., & Bard, F. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214118 · Cited by 27
Zhou, R. W., Purohit, P. K., Kim, J. H., Lee, S.-U., Burshteyn, N., Tifrea, D. F., Cordon, A., Grigorian, A., Newton, B. L., Edwards, R. A., et al. (2025) · Cell · doi:10.1016/j.cell.2025.09.001 · Cited by 28
Wang, Y., Ren, S., Jiang, W., Lu, J., Zhang, X., Li, X., Cao, R., & Xu, C. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-8053 · Cited by 25
“Tn antigen is an O-glycan structure demonstrated to be upregulated in many malignant tissues (33,34).”
BackgroundSelf-citationZhang, P., Li, K., Yang, G., Xia, C., Polston, J. E., Li, G., Li, S., Zhao, L., Yang, L., Bruner, S. D., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706894114 · Cited by 25
“However, Y3 showed only weak binding to GalNAc itself, also known as Tn antigen that is commonly found on cancer cells (46).”
BackgroundYang, W., Ao, M., Song, A., Xu, Y., Sokoll, L. J., & Zhang, H. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c01564 · Cited by 24
“It may involve glycosyltransferase C1GalT1 and its chaperone C1GalT1C1 also called Cosmc (30).”
BackgroundInfluentialKudelka, M. R., Nairn, A. V., Sardar, M. Y. R., Sun, X., Chaikof, E. L., Ju, T., Moremen, K. W., & Cummings, R. D. (2018) · Glycobiology · doi:10.1093/glycob/cwy005 · Cited by 23
Self-citationLung cancer molecular mutations and abnormal glycosylation as biomarkers for early diagnosis
Yang, S., Xia, J., Yang, Z., Xu, M., & Li, S. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100311 · Cited by 24
Plant Lectins with Insecticidal and Insectistatic Activities
Reyes-Montaño, E. A., & Vega, N. A. (2018) · InTech eBooks · doi:10.5772/intechopen.74962 · Cited by 23
Probing sialoglycans on fetal bovine fetuin with azido-sugars using glycosyltransferases
Wu, Z. L., Huang, X., Burton, A. J., & Swift, K. A. D. (2015) · Glycobiology · doi:10.1093/glycob/cwv109 · Cited by 21
Cosmc overexpression enhances malignancies in human colon cancer
Gao, T., Du, T., Hu, X. Y., Dong, X., Li, L., Wang, Y., Liu, J., Liu, L., Gu, T., & Wen, T. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14740 · Cited by 23
Self-citationDu, T., Jia, X., Dong, X., Ru, X., Li, L., Wang, Y., Liu, J., Feng, G., & Wen, T. (2020) · Cancer Management and Research · doi:10.2147/cmar.s234735 · Cited by 22
Self-citationGermline C1GALT1C1 mutation causes a multisystem chaperonopathy
Erger, F., Aryal, R. P., Reusch, B., Matsumoto, Y., Meyer, R., Zeng, J., Knopp, C., Noël, M., Muerner, L., Wenzel, A., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211087120 · Cited by 20
“Exposure of the abnormal Tn-antigen likely leads to an autoantibody-mediated cytotoxic immune response (24).”
BackgroundSelf-citationAlteration of liver glycopatterns during cirrhosis and tumor progression induced by HBV
Qin, Y., Zhong, Y., Ma, T., Wu, F., Wu, H., Yu, H., Huang, C., & Li, Z. (2016) · Glycoconjugate Journal · doi:10.1007/s10719-015-9645-z · Cited by 20
“The level of Tn/T antigen and sialyl-Tn/T expression often correlates well with carcinoma differentiation and aggressiveness [25, 26].”
Deciphering Protein O-GalNAcylation: Method Development and Disease Implication
Yue, S., Wang, X., Ge, W., Li, J., Yang, C., Zhou, Z., Zhang, P., Yang, X., Xiao, W., & Yang, S. (2023) · ACS Omega · doi:10.1021/acsomega.3c01653 · Cited by 21
Tn antigen interactions of macrophage galactose-type lectin (MGL) in immune function and disease
Tumoglu, B., Keelaghan, A. P., & Avci, F. Y. (2023) · Glycobiology · doi:10.1093/glycob/cwad083 · Cited by 22
Kozani, P. S., Kozani, P. S., & Rahbarizadeh, F. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0901-2 · Cited by 20
The role and potential mechanism of O-Glycosylation in gastrointestinal tumors
Zhou, F., Ma, J., Zhu, Y., Wang, T., Yang, Y., Sun, Y., Chen, Y., Song, H., Huo, X., & Zhang, J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106420 · Cited by 23
Rømer, T. B., Khoder‐Agha, F., Aasted, M. K. M., de Haan, N., Horn, S., Dylander, A., Zhang, T., Pallesen, E. M. H., Dabelsteen, S., Wuhrer, M., et al. (2023) · Glycobiology · doi:10.1093/glycob/cwad003 · Cited by 20
“Accordingly, increased expression of Tn and sialylation in tumors has been shown to induce immune escape, metastasis, and tumor formation (Büll et al. 2014; Ju et al. 2014; Radhakrishnan et al. 2014; Bhide and Colley 2017).”
BackgroundNapoletano, C., Steentoff, C., Battisti, F., Ye, Z., Rahimi, H., Zizzari, I. G., Dionisi, M., Cerbelli, B., Tomao, F., French, D., et al. (2020) · Cancers · doi:10.3390/cancers12102841 · Cited by 22
“Multiple molecular mechanisms can account for the altered glycan biosynthesis: hypermethylation or somatic mutation of core 1, β3‐Gal‐T‐specific molecular chaperone (COSMC), required for the elongation of mature O‐glycans [8], or translocation of polypeptide GalNAc‐ transferases (GalNAc‐Ts) from Golgi to endoplasmic r…”
BackgroundHighly specific lubricin-lectin electrochemical sensor for glycoprotein cancer biomarker detection
Li, M., Abeyrathne, C. D., Langley, D., Cossins, L. R., Samudra, A. N., Greene, G. W., Moulton, S. E., & Silva, S. M. (2023) · Electrochimica Acta · doi:10.1016/j.electacta.2023.142508 · Cited by 17
Cancer snap-shots: Biochemistry and glycopathology of O-glycans: A review
Sanji, A. S., Manasa, J., Gurav, M. J., Batra, S. K., & Chachadi, V. B. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.129318 · Cited by 18
Differential expression of CD175 and CA19-9 in pancreatic adenocarcinoma
Cheng, J. J., Matsumoto, Y., Dombek, G. E., Stackhouse, K. A., Ore, A. S., Glickman, J. N., Heimburg‐Molinaro, J., & Cummings, R. D. (2025) · Scientific Reports · doi:10.1038/s41598-025-86988-8 · Cited by 19
“Its expression in PDACs is largely due to epigenetic silencing of the X-linked gene COSMC ( C1GALT1C1 ) 17 , which encodes the molecular chaperone Cosmc that is required for the extension of normal O-glycans through action of the T-synthase that modifies and masks CD175 18 .”
Self-citationAmplification and Preparation of Cellular O-Glycomes for Functional Glycomics
Li, Z., Zhang, Q., Ashline, D. J., Zhu, Y., Lasanajak, Y., Chernova, T. A., Reinhold, V. N., Cummings, R. D., Wang, P. G., Ju, T., et al. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c00632 · Cited by 17
Self-citationTuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer
Park, S., Ho, C. E., Darnell, E. P., Wolff, A. N., Takei, H., Birocchi, F., Bouffard, A. A., Salas‐Benito, D., Escobar, G., Leick, M. B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66102-2 · Cited by 22
“Due to this characteristic overexpression pattern, the Tn antigen serves as a potential biomarker for early prediction or detection of human cancers 52,53 .”
Zhang, S.-Z., Lobo, A. J., Li, P., & Zhang, Y. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104330 · Cited by 17
Aco-Tlachi, M., Carreño-López, R., Martínez‐Morales, P., Maycotte, P., Aguilar‐Lemarroy, A., Jave‐Suárez, L. F., Santos‐López, G., Reyes‐Leyva, J., & Vallejo‐Ruiz, V. (2018) · Infectious Agents and Cancer · doi:10.1186/s13027-018-0197-2 · Cited by 18
A roadmap for translational cancer glycoimmunology at single cell resolution
Peixoto, A., Miranda, A., Santos, L. L., & Ferreira, J. A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02335-z · Cited by 16
Targeting Siglec–Sialylated MUC1 Immune Axis in Cancer
Ayyalasomayajula, R., & Čudić, M. (2024) · Cancers · doi:10.3390/cancers16071334 · Cited by 20
“The most common modifications to glycosylation include the enhanced expression of truncated or incomplete glycans, often terminated by sialic acid, and an aberrant fucosylation pattern [5–7].”
Backgroundda Costa, V., Mariño, K. V., Rodríguez-Zraquia, S. A., Festari, M. F., Lores, P., Costa, M., Landeira, M., Rabinovich, G. A., van Vliet, S. J., & Freire, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231912047 · Cited by 13
“It has been used for understanding the role of Tn antigen in tumor development by knocking out Cosmc, a strategy that efficiently induces expression of the Tn antigen [8,9,26,27].”
MethodTargeting Tn-positive tumors with an afucosylated recombinant anti-Tn IgG
Matsumoto, Y., Jia, N., Heimburg‐Molinaro, J., & Cummings, R. D. (2023) · Scientific Reports · doi:10.1038/s41598-023-31195-6 · Cited by 18
Self-citationTargeting altered glycosylation in secreted tumor glycoproteins for broad cancer detection
Kudelka, M. R., Gu, W. Y., Matsumoto, Y., Ju, T., Barnes, R. H., II, Kardish, R., Heimburg‐Molinaro, J., Lehoux, S. D., Zeng, J., Cohen, C., et al. (2023) · Glycobiology · doi:10.1093/glycob/cwad035 · Cited by 13
Self-citationHaugstad, K. E., Hadjialirezaei, S., Stokke, B. T., Brewer, C. F., Gerken, T. A., Burchell, J., Picco, G., & Sletmoen, M. (2016) · Glycobiology · doi:10.1093/glycob/cww065 · Cited by 13
“Whereas the abnormal glycosylation is believed to be due to changes in topology, function and expression of glycosyltransferases and chaperones (Brockhausen 2006; Ju et al. 2014), the understanding of the biological significance of these truncated glycan side chains is still incomplete.”
BackgroundSubstrate O‐glycosylation actively regulates extracellular proteolysis
Madzharova, E., Sabino, F., Kalogeropoulos, K., Francavilla, C., & Keller, U. A. D. (2024) · Protein Science · doi:10.1002/pro.5128 · Cited by 16
“Together, these global changes in the proteolytic network potentially contribute to the phenotype of cancer cells with high levels of Tn antigen as a result of impaired COSMC function (Ju et al., 2014).”
BackgroundIncreased sialylation of site specific O-glycoforms of hemopexin in liver disease
Šanda, M., Benický, J., Wu, J., Wang, Y., Makambi, K. H., Ahn, J., Smith, C. I., Zhao, P., Zhang, L., & Goldman, R. (2016) · Clinical Proteomics · doi:10.1186/s12014-016-9125-x · Cited by 12
“Increased sialylation of site specific O-glycoforms of hemopexin in liver disease Miloslav Sanda 1 , Julius Benicky 2 , Jing Wu 2 , Yiwen Wang 2 , Kepher Makambi 3 , Jaeil Ahn 4 Background Hepatitis C virus (HCV) is a leading cause of chronic liver disease in the US [1] [2].”
Self-citationEmerging Roles of the Unique Molecular Chaperone Cosmc in the Regulation of Health and Disease
Xiang, T., Qiao, M., Xie, J., Li, Z., & Xie, H. (2022) · Biomolecules · doi:10.3390/biom12121732 · Cited by 14
Endocytic Roles of Glycans on Proteins and Lipids
Johannes, L., Shafaq‐Zadah, M., Dransart, E., Wunder, C., & Leffler, H. (2023) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041398 · Cited by 13
Glycan diversity in ovarian cancer: Unraveling the immune interplay and therapeutic prospects
Wolters‐Eisfeld, G., & Oliveira‐Ferrer, L. (2024) · Seminars in Immunopathology · doi:10.1007/s00281-024-01025-6 · Cited by 13
“The correct folding of T-Synthase is facilitated by a chaperone called COSMC (Core 1-Specific-Molecular-Chap-erone) [51].”
BackgroundCull, J., Pink, R. C., Samuel, P., & Brooks, S. A. (2025) · Glycobiology · doi:10.1093/glycob/cwaf023 · Cited by 18
Květoň, F., Blšáková, A., Hushegyi, A., Damborský, P., Blixt, O., Jansson, B., & Tkáč, J. (2017) · Langmuir · doi:10.1021/acs.langmuir.6b04021 · Cited by 11
Synthesis and Characterization of Versatile O-Glycan Precursors for Cellular O-Glycomics
Zhang, Q., Li, Z., Chernova, T., Saikam, V., Cummings, R. D., Song, X., Ju, T., Smith, D. F., & Wang, P. G. (2019) · ACS Synthetic Biology · doi:10.1021/acssynbio.9b00168 · Cited by 10
Self-citationLiu, L., Li, D., Shu, J. H., Wang, L., Zhang, F., Zhang, C., Yu, H., Chen, T., Chen, M., Li, Z., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.568433 · Cited by 11
“The expression of this antigen found in most human carcinomas is derived from blockade during the normal O-glycosylation pathway, in which glycans extend from the common precursor GalNAca1-O-Ser/Thr (Tn antigen) (52).”
BackgroundXu, F., Wang, D., Cui, J., Li, J., & Jiang, H. (2020) · Cancer Management and Research · doi:10.2147/cmar.s214553 · Cited by 9
“The absence of Cosmc contributes to the expression of the Tn antigen through the regulation of T-synthase, which is related to the development and progression of various human diseases, including cancer.(34,35) For instance, a recent study has found that Cosmc deficient pancreatic cancer cell line”
BackgroundRetractedPotential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy
Madsen, C. B., Wandall, H. H., & Pedersen, A. E. (2013) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2013.837060 · Cited by 9
Single molecule study of heterotypic interactions between mucins possessing the Tn cancer antigen
Haugstad, K. E., Stokke, B. T., Brewer, C. F., Gerken, T. A., & Sletmoen, M. (2014) · Glycobiology · doi:10.1093/glycob/cwu183 · Cited by 11
“The mucins in Table I possess glycan side chains ranging from the 100% monosaccharide Tn structure (Tn-PSM) to an unmodified mucin containing a range of structures including the Tn an STn antigens, and core 1 blood group A tetrasaccharide (Fd-PSM) (structures in Table I are based, in part, on the biosynthetic summary…”
BackgroundShi, C., Xu, X., Yu, X., Du, Z., Luan, X., Liu, D., & Hu, T. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.06.250 · Cited by 9
Representing glycophenotypes: semantic unification of glycobiology resources for disease discovery
Gourdine, J.-P. F., Brush, M., Vasilevsky, N., Shefchek, K., Köhler, S., Matentzoglu, N., Muñoz-Torres, M. C., McMurry, J. A., Zhang, X., Robinson, P. N., et al. (2019) · Database · doi:10.1093/database/baz114 · Cited by 10
“Challenges with an ontological representation of glycophenotypes A robust and comprehensive glycophenotype ontological representation would (i) provide synonyms of glycans between disciplines (e.g. Tn antigen or O linked Nacetylgalactosaminyl epitope or O-GalNAc (114)); (ii) gather identifiers (GlyTouCan, Kegg, CHEBI,…”
BackgroundKurogochi, M., Matsuda, A., & Mizuno, M. (2020) · Carbohydrate Research · doi:10.1016/j.carres.2020.107981 · Cited by 9
Metadata
- Authors
- Ju, T., Aryal, R. P., Kudelka, M. R., Wang, Y., & Cummings, R. D.
- Affiliations
- Emory University (US)
- Corresponding author
- Cummings, Richard D.
- Venue
- Cancer Biomarkers
- Publisher
- SAGE Publications
- Published
- 2014-02-27
- Volume
- 14
- Issue
- 1
- Pages
- 63-81
- ISSN
- 1574-0153 (ISSN-L)
- 1875-8592
- PMC
- PMC5808877
- OpenAlex
- W1544375765
- Cited by
- 153
- References
- 202
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 11 · 2023: 22 · 2022: 14 · 2021: 14 · 2020: 18 · 2019: 14 · 2018: 10 · 2017: 5 · 2016: 11 · 2015: 7 · 2014: 2
- FWCI
- 3.41
- Type
- journal article
- Language
- en
- Open access
- Locations
- Cancer Biomarkers (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (U01CA168930)
- National Institute of General Medical Sciences (T32GM008169, R24GM098791)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Keywords
- Tn antigen, sialyl-Tn antigen, Cosmc, T-synthase, O-glycosylation, tumor-associated carbohydrate antigens, X chromosome, molecular chaperones, protein misfolding, epigenetic regulation
- MeSH terms
- Animals, Carbohydrate Sequence, Glycosylation, Humans, Neoplasms, Polysaccharides, Antigens, Tumor-Associated, Carbohydrate, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.